Table 5 Characteristics of preferred clinical trials*
From: Factors influencing the participation of gastroenterologists and hepatologists in clinical research
Characteristic | Specialty | Experience | ||
|---|---|---|---|---|
| Â | Gastroenterology (n = 160) | Hepatology (n = 189) | Less Experienced Researchers (n = 159) | More Experienced Researchers (n = 62) |
Phase 1 trials | 36 (22.5)†| 73 (38.6)†| 59 (37.1)†| 32 (51.6)†|
Phase 2 trials | 64 (40.0)†| 107 (56.6)†| 91 (57.2)†| 52 (83.9)†|
Phase 3 trials | 97 (60.6) | 108 (57.1) | 114 (71.7)†| 53 (85.5)†|
Phase 4 trials | 76 (47.5)†| 68 (36.0)†| 92 (57.9) | 28 (45.2) |
Duration ≤ 2 years | 100 (62.5) | 126 (66.7) | 127 (79.9)†| 58 (93.6)†|
Duration > 2 years | 38 (23.8) | 59 (31.2) | 57 (35.9)†| 35 (56.5)†|
Trials with placebo or no treatment arm | 51 (31.9) | 55 (29.1) | 68 (42.8) | 28 (45.2) |
Trials involving invasive procedures | 40 (25.0)†| 30 (15.9)†| 44 (27.7) | 18 (29.0) |
Multiple-arm and crossover protocols | 36 (22.5) | 35 (18.5) | 40 (25.2)†| 24 (38.7) |
Industry funding | 76 (47.5) | 104 (55.0) | 86 (54.1)†| 50 (80.7)†|
Government funding | 78 (48.8)†| 121 (64.0)†| 104 (65.4)†| 56 (90.3)†|
Non-government funding | 78 (48.8) | 103 (54.5) | 96 (60.4)†| 51 (82.3)†|